Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer.

Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL, Wong GYC.

Oncol Lett. 2017 Apr;13(4):2477-2482. doi: 10.3892/ol.2017.5720. Epub 2017 Feb 13.

2.

Evaluation of 3,3'-diindolylmethane with gardasil quadrivalent HPV vaccine in K14-HPV16-transgenic mice cervical histology.

Sepkovic DW, Pagan DV, Stein J, Carlisle AD, Ksieski HB, Auborn K, Nyirenda T, Bradlow HL.

In Vivo. 2013 May-Jun;27(3):299-304.

PMID:
23606684
3.

Polychlorinated biphenyl exposure, diabetes and endogenous hormones: a cross-sectional study in men previously employed at a capacitor manufacturing plant.

Persky V, Piorkowski J, Turyk M, Freels S, Chatterton R Jr, Dimos J, Bradlow HL, Chary LK, Burse V, Unterman T, Sepkovic DW, McCann K.

Environ Health. 2012 Aug 29;11:57.

4.

3,3'-Diindolylmethane increases serum interferon-γ levels in the K14-HPV16 transgenic mouse model for cervical cancer.

Sepkovic DW, Raucci L, Stein J, Carlisle AD, Auborn K, Ksieski HB, Nyirenda T, Bradlow HL.

In Vivo. 2012 Mar-Apr;26(2):207-11.

PMID:
22351660
5.

Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer.

Telang NT, Li G, Sepkovic DW, Bradlow HL, Wong GY.

Mol Med Rep. 2012 Jan;5(1):22-8. doi: 10.3892/mmr.2011.617. Epub 2011 Oct 4.

PMID:
21971582
6.
7.

Results from a dose-response study using 3,3'-diindolylmethane in the K14-HPV16 transgenic mouse model: cervical histology.

Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Raucci L, Nyirenda T, Bradlow HL.

Cancer Prev Res (Phila). 2011 Jun;4(6):890-6. doi: 10.1158/1940-6207.CAPR-10-0369. Epub 2011 Mar 7.

8.

3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study.

Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK.

Thyroid. 2011 Mar;21(3):299-304. doi: 10.1089/thy.2010.0245. Epub 2011 Jan 22.

9.

Effects of a breast-health herbal formula supplement on estrogen metabolism in pre- and post-menopausal women not taking hormonal contraceptives or supplements: a randomized controlled trial.

Laidlaw M, Cockerline CA, Sepkovic DW.

Breast Cancer (Auckl). 2010 Dec 16;4:85-95. doi: 10.4137/BCBCR.S6505. Erratum in: Breast Cancer (Auckl). 2012;6:101.

10.

Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model.

Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Bradlow HL.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2957-64. doi: 10.1158/1055-9965.EPI-09-0698. Epub 2009 Oct 27. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):628.

11.

Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism.

Li G, Sepkovic DW, Bradlow HL, Telang NT, Wong GY.

Nutr Cancer. 2009;61(3):408-14. doi: 10.1080/01635580802585952.

PMID:
19373615
12.

Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women.

Teas J, Hurley TG, Hebert JR, Franke AA, Sepkovic DW, Kurzer MS.

J Nutr. 2009 May;139(5):939-44. doi: 10.3945/jn.108.100834. Epub 2009 Mar 25. Erratum in: J Nutr. 2009 Sep;139(9):1779.

PMID:
19321575
13.

Estrogen hydroxylation--the good and the bad.

Sepkovic DW, Bradlow HL.

Ann N Y Acad Sci. 2009 Feb;1155:57-67. doi: 10.1111/j.1749-6632.2008.03675.x. Review.

PMID:
19250192
14.

Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11.

Dhar M, Sepkovic DW, Hirani V, Magnusson RP, Lasker JM.

J Lipid Res. 2008 Mar;49(3):612-24. Epub 2007 Dec 7.

15.

Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer.

Greenlee H, Chen Y, Kabat GC, Wang Q, Kibriya MG, Gurvich I, Sepkovic DW, Bradlow HL, Senie RT, Santella RM, Ahsan H.

Breast Cancer Res Treat. 2007 Mar;102(1):111-7. Epub 2006 Jul 19.

PMID:
16850246
16.

A hormonal association between estrogen metabolism and proliferative thyroid disease.

Chan EK, Sepkovic DW, Yoo Bowne HJ, Yu GP, Schantz SP.

Otolaryngol Head Neck Surg. 2006 Jun;134(6):893-900.

PMID:
16730526
17.

Estrogen metabolism and breast cancer.

Kabat GC, O'Leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, Terry MB, Neugut AI, Bradlow HL.

Epidemiology. 2006 Jan;17(1):80-8.

PMID:
16357599
18.

Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina.

Teas J, Cunningham JE, Fowke JH, Nitcheva D, Kanwat CP, Boulware RJ, Sepkovic DW, Hurley TG, Hebert JR.

Cancer Detect Prev. 2005;29(6):494-500. Epub 2005 Nov 10.

PMID:
16289388
19.

A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio.

Paracchini V, Pedotti P, Raimondi S, Garte S, Bradlow HL, Sepkovic DW, Taioli E.

Clin Chem Lab Med. 2005;43(7):702-6.

PMID:
16207128
20.

Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites.

Bradlow HL, Jernström H, Sepkovic DW, Klug TL, Narod SA.

Mol Genet Metab. 2006 Feb;87(2):135-46. Epub 2005 Sep 13.

PMID:
16165383
21.

Urinary estrogen metabolites and their ratio among Asian American women.

Falk RT, Fears TR, Xu X, Hoover RN, Pike MC, Wu AH, Nomura AM, Kolonel LN, West DW, Sepkovic DW, Bradlow HL, Ziegler RG.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):221-6.

22.

Steroids as procarcinogenic agents.

Bradlow HL, Sepkovic DW.

Ann N Y Acad Sci. 2004 Dec;1028:216-32. Review.

PMID:
15650248
23.

Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.

Alvarez-Vasquez RB, Axelrod D, Frenkel K, Newman MC, Sepkovic DW, Bradlow HL, Zumoff B.

Horm Metab Res. 2003 Jun;35(6):358-61.

PMID:
12920658
24.

Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups.

Jernström H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA.

Carcinogenesis. 2003 May;24(5):991-1005.

PMID:
12771045
25.

Diet and breast cancer.

Bradlow HL, Sepkovic DW.

Ann N Y Acad Sci. 2002 Jun;963:247-67.

PMID:
12095951
26.

Quantitative determination of 3,3'-diindolylmethane in urine of individuals receiving indole-3-carbinol.

Sepkovic DW, Bradlow HL, Bell M.

Nutr Cancer. 2001;41(1-2):57-63.

PMID:
12094629
27.

Effect of soy protein on endogenous hormones in postmenopausal women.

Persky VW, Turyk ME, Wang L, Freels S, Chatterton R Jr, Barnes S, Erdman J Jr, Sepkovic DW, Bradlow HL, Potter S.

Am J Clin Nutr. 2002 Jan;75(1):145-53. Erratum in: Am J Clin Nutr 2002 Sep;76(3):695.

PMID:
11756072
28.

Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women.

Riza E, dos Santos Silva I, De Stavola B, Bradlow HL, Sepkovic DW, Linos D, Linos A.

Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):627-34.

29.

Estrogen metabolism as a risk factor for head and neck cancer.

Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP.

Otolaryngol Head Neck Surg. 2001 Mar;124(3):241-7.

PMID:
11240983
30.

Estrone and estradiol metabolism in vivo in human breast cysts.

Raju U, Sepkovic DW, Miller WR, Dixon JM, Bradlow HL, Levitz M.

Steroids. 2000 Dec;65(12):883-8.

PMID:
11077086
31.

Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.

Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F.

Epidemiology. 2000 Nov;11(6):635-40.

PMID:
11055622
32.

Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.

Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM.

Gynecol Oncol. 2000 Aug;78(2):123-9.

PMID:
10926790
33.

Phytochemicals as modulators of cancer risk.

Bradlow HL, Telang NT, Sepkovic DW, Osborne MP.

Adv Exp Med Biol. 1999;472:207-21. Review.

PMID:
10736628
34.

Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent.

Bradlow HL, Sepkovic DW, Telang NT, Osborne MP.

Ann N Y Acad Sci. 1999;889:204-13. Review.

PMID:
10668495
35.

A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid.

Falk RT, Rossi SC, Fears TR, Sepkovic DW, Migella A, Adlercreutz H, Donaldson J, Bradlow HL, Ziegler RG.

Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):81-7.

36.

Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period.

Michaud DS, Manson JE, Spiegelman D, Barbieri RL, Sepkovic DW, Bradlow HL, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1059-64.

37.

Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer.

Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL, Auborn K.

Anticancer Res. 1999 May-Jun;19(3A):1673-80.

PMID:
10470100
38.

Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk.

Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, Ganguly S, Garte SJ.

Cancer Detect Prev. 1999;23(3):232-7.

PMID:
10337002
39.

Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up.

Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH.

Br J Cancer. 1998 Nov;78(9):1250-5.

40.

Application of an improved ELISA assay to the analysis of urinary estrogen metabolites.

Bradlow HL, Sepkovic DW, Klug T, Osborne MP.

Steroids. 1998 Jul-Aug;63(7-8):406-13.

PMID:
9654647
41.

Role of the estrogen receptor in the action of organochlorine pesticides on estrogen metabolism in human breast cancer cell lines.

Bradlow HL, Davis D, Sepkovic DW, Tiwari R, Osborne MP.

Sci Total Environ. 1997 Dec 3;208(1-2):9-14.

PMID:
9496644
42.

Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes.

Newfield L, Bradlow HL, Sepkovic DW, Auborn K.

Proc Soc Exp Biol Med. 1998 Mar;217(3):322-6.

PMID:
9492342
44.

Re: Ethnic differences in estrogen metabolism in healthy women.

Coker AL, Crane MM, Sticca RP, Sepkovic DW.

J Natl Cancer Inst. 1997 Jan 1;89(1):89-90. No abstract available.

PMID:
8978414
45.

2-hydroxyestrone: the 'good' estrogen.

Bradlow HL, Telang NT, Sepkovic DW, Osborne MP.

J Endocrinol. 1996 Sep;150 Suppl:S259-65. Review.

PMID:
8943806
46.

Urinary markers of estrogen metabolism 2- and 16 alpha-hydroxylation in premenopausal women.

Pasagian-Macaulay A, Meilahn EN, Bradlow HL, Sepkovic DW, Buhari AM, Simkin-Silverman L, Wing RR, Kuller LH.

Steroids. 1996 Aug;61(8):461-7.

PMID:
8870165
47.

Ethnic differences in estrogen metabolism in healthy women.

Taioli E, Garte SJ, Trachman J, Garbers S, Sepkovic DW, Osborne MP, Mehl S, Bradlow HL.

J Natl Cancer Inst. 1996 May 1;88(9):617. No abstract available.

PMID:
8609664
48.

Estrogen metabolite ratios and risk assessment of hormone-related cancers. Assay validation and prediction of cervical cancer risk.

Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, Osborne MP, Fishman J.

Ann N Y Acad Sci. 1995 Sep 30;768:312-6. No abstract available.

PMID:
8526376
49.

Indole-3-carbinol. A novel approach to breast cancer prevention.

Bradlow HL, Sepkovic DW, Telang NT, Osborne MP.

Ann N Y Acad Sci. 1995 Sep 30;768:180-200. Review.

PMID:
8526347
50.

Supplemental Content

Loading ...
Support Center